An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer

An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer

Show other versions (1)

Background Although combining targeted agents with conventional, first-line cytotoxic therapy has improved survival outcomes in patients with advanced colorectal cancer, further improvements in outcomes and tolerability are needed. Methods This phase I study evaluated the feasibility of combining or...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Brady, J, Corrie, P, Chau, I, Digumarti, R, Adams, L, Botbyl, J, Laubscher, K, Midgley, R, Mallath, M
Formatua:	Journal article
Hizkuntza:	English
Argitaratua:	2013

Antzeko izenburuak

An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.
nork: Brady, J, et al.
Argitaratua: (2013)

A phase I study of pazopanib in combination with FOLFOX 6 or capeOx in subjects with colorectal cancer
nork: Brady, J, et al.
Argitaratua: (2009)

CapeOX as neoadjuvant chemotherapy for locally advanced rectal cancer: might less be more?
nork: Tianan Guo, et al.
Argitaratua: (2024-10-01)

Gut microbiome associated with chemotherapy-induced diarrhea from the CapeOX regimen as adjuvant chemotherapy in resected stage III colorectal cancer
nork: Zuo Fei, et al.
Argitaratua: (2019-04-01)

Case Report: Primary small bowel adenocarcinoma with peritoneal metastasis responded well to a CapeOX + bevacizumab regimen
nork: Guang Fu, et al.
Argitaratua: (2023-08-01)

Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study
nork: Xuefeng Fang, et al.
Argitaratua: (2023-07-01)

An Observational Study of Team Management Approach for CapeOX Therapy in Patients with Advanced and Recurrent Colorectal Cancer: SMILE Study (The Study of Metastatic colorectal cancer to investigate the Impact of Learning Effect)
nork: Hiroshi Matsuoka, et al.
Argitaratua: (2020-04-01)

Temozolomide and Pazopanib Combined with FOLFOX Regressed a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model
nork: Guangwei Zhu, et al.
Argitaratua: (2020-03-01)

The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)
nork: Goro Nakayama, et al.
Argitaratua: (2017-04-01)

Effects on Cardiac Biomarkers in Colorectal Cancer Patients Treated With FOLFOX
nork: Nusrat Bano, et al.
Argitaratua: (2024-05-01)

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran
nork: Abdosaleh Jafari, et al.
Argitaratua: (2023-05-01)

Thrombotic Thrombocytopenic Purpura Associated with Pazopanib
nork: Umer Syed, et al.
Argitaratua: (2018-01-01)

Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement
nork: Chua Daniel TT, et al.
Argitaratua: (2011-07-01)

Hematologic Toxicities in Colorectal Cancer Patients who Received FOLFOX4
nork: Mehdi Dehghani, et al.
Argitaratua: (2015-07-01)

Patient-reported outcomes in PROSPECT trial (Alliance N1048) – FOLFOX is not a panacea
nork: Sean M. O'Cathail, et al.
Argitaratua: (2023-11-01)

Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases: protocol of the multicentre, open-label, phase II, INTERACT-II trial
nork: Jacobus W A Burger, et al.
Argitaratua: (2024-01-01)

Effect of CAPEOX combined with thalidomide in the treatment of elderly patients with colon cancer: A single-center report
nork: Ni Zhong, et al.
Argitaratua: (2024-08-01)

Quality of life in non-metastasic colorectal cancer patients in FOLFOX or XELOX therapy
nork: Julia Sánchez-Gundín, et al.
Argitaratua: (2019-03-01)

Global impact of KRAS mutations patterns in FOLFOX treated metastatic colorectal cancer
nork: David eMolinas Zocche, et al.
Argitaratua: (2015-03-01)

Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells
nork: Teresa Di Desidero, et al.
Argitaratua: (2019-11-01)

Preoperative Nutritional Status Contributes to the Development of Neutropenia Event in Patients With Gastric Cancer Receiving CAPEOX Adjuvant Chemotherapy
nork: Ai Tang Xiao, et al.
Argitaratua: (2020-04-01)

Pazopanib and Statin-Induced Rhabdomyolysis
nork: Jennifer M. Logue, et al.
Argitaratua: (2017-10-01)

Phototoxic Reaction Induced by Pazopanib
nork: Siriorn Udompanich, et al.
Argitaratua: (2018-11-01)

Dynamic impact of inﬂammation-based indices in colorectal cancer patients receiving FOLFOX-based chemotherapy
nork: Tao Y, et al.
Argitaratua: (2019-04-01)

Probiotics Enhance FOLFOX Efficacy Via Gut Bacterial Tryptophan Metabolism in Colorectal Cancer
nork: Deng Yufei, et al.
Argitaratua: (2024-01-01)

miRNAs and lncRNAs as Predictive Biomarkers of Response to FOLFOX Therapy in Colorectal Cancer
nork: Kha Wai Hon, et al.
Argitaratua: (2018-08-01)

Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial
nork: Urbonas, V, et al.
Argitaratua: (2018)

A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol
nork: Jinjie He MD, et al.
Argitaratua: (2023-02-01)

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
nork: Bai L, et al.
Argitaratua: (2019-12-01)

Translational analysis and final efficacy of the AVETUX trial – Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
nork: Joseph Tintelnot, et al.
Argitaratua: (2022-12-01)

Prediction of resistance to bevacizumab plus FOLFOX in metastatic colorectal cancer-Results of the prospective multicenter PERMAD trial.
nork: Thomas Seufferlein, et al.
Argitaratua: (2024-01-01)

Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6
nork: Vedin Barve, et al.
Argitaratua: (2021-10-01)

Bilateral rhegmatogenous retinal detachments in a patient taking pazopanib: A case report
nork: Nolan J. Adams, et al.
Argitaratua: (2022-06-01)

Pazopanib-induced alopecia, an underestimated toxicity?
nork: Andrea eBiondo, et al.
Argitaratua: (2015-05-01)

Pazopanib for the treatment of soft-tissue sarcoma
nork: Heudel P, et al.
Argitaratua: (2012-10-01)

Pazopanib-Induced Severe Acute Pancreatitis
nork: Kazumichi Kawakubo, et al.
Argitaratua: (2015-08-01)

Triggering of Suicidal Erythrocyte Death by Pazopanib
nork: Elena Signoretto, et al.
Argitaratua: (2016-03-01)

Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial
nork: Jii Bum Lee, et al.
Argitaratua: (2020-04-01)

A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer.
nork: Sabharwal, A, et al.
Argitaratua: (2010)

Global Proteome Changes in Liver Tissue 6 Weeks after FOLFOX Treatment of Colorectal Cancer Liver Metastases
nork: Jozef Urdzik, et al.
Argitaratua: (2016-10-01)